Stroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular
complication has been less carefully investigated than the risk of cardiovascular mortality …

Purpose Chronic kidney disease (CKD) is one of the most common complications of type 2
diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent …

Patients with type 2 diabetes mellitus (T2DM) are exposed to a high risk of atherosclerotic
cardiovascular disease, heart failure and chronic kidney disease. The incidence of these …

Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium glucose
cotransporter-2 inhibitors (SGLT-2i) demonstrated cardiovascular and renal protection …

Background The purpose of this systematic review and meta-analysis was to evaluate the
common clinical adverse events associated with sodium/glucose cotransporter-2 inhibitor …

Cardiovascular complications and renal disease is the growing cause of mortality in patients
with diabetes. The subversive complications of diabetes such as hyperglycemia …

Aim Studies examining the safety and effectiveness of sodium‐glucose cotransporter‐2
inhibitors (SGLT2is) versus glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among …

Different multifactorial pathophysiological processes are involved in the development of
heart failure (HF), including neurohormonal dysfunction, the hypertrophy of cardiomyocytes …

No randomized clinical trials have directly compared the cardiorenal effectiveness of
empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients …

Context The coexistence of diabetes mellitus and atrial fibrillation (AF) is associated with
substantial risks of adverse cardiovascular events. Objective The relevant outcomes …